Related Experiment Video
Updated: Oct 8, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.8K
[CME/Answers: Metformin - Dos and Don'ts]
1Departement Medizin, Luzerner Kantonsspital, Luzern.
Praxis
|January 5, 2022
Summary
Metformin is a first-line medication for type 2 diabetes, offering glycemic control and weight reduction without hypoglycemia risk. Careful consideration of contraindications, especially renal impairment, is crucial to prevent rare but serious complications like lactic acidosis.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Metformin remains a cornerstone in type 2 diabetes management.
- Its role persists despite evolving diabetes treatment landscapes.
Purpose of the Study:
- To review the indications and contraindications of metformin therapy.
- To highlight safe and effective metformin use in clinical practice.
Main Methods:
- Review of current clinical guidelines and literature on metformin.
- Analysis of metformin's mechanism of action, benefits, and risks.
Main Results:
- Metformin improves glycemic control by inhibiting gluconeogenesis and enhancing insulin sensitivity.
- Advantages include weight reduction, no hypoglycemia risk, good tolerability, and low cost.
- Gastrointestinal side effects and vitamin B12 deficiency are potential issues; lactic acidosis is a rare but severe risk, particularly with renal impairment.
Conclusions:
- Metformin is a valuable first-line agent for type 2 diabetes when contraindications are absent.
- Dosage adjustment based on estimated glomerular filtration rate (eGFR) is essential.
- Awareness of contraindications like severe renal impairment, liver disease, and heart failure is critical for patient safety.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
334
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
334
01:16Insulin: Dosing Regimen and Adverse Effects
296
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
296
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
307
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
307
01:06Oral Hypoglycemic Agents: Glinides
291
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
291
01:17Oral Hypoglycemic Agents: Sulfonylureas
382
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
382
01:22Diabetes Mellitus: Type 2 and Gestational
3.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.1K